Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Giulio Modorati(Ophthalmology Associates (United States)), Luca Arcaini(University of Pavia), Caterina Cecchetti, Donato Mannina(Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte), Francesco Zaja, Silvia Govi, Elisabetta Miserocchi(Vita-Salute San Raffaele University), Silvia Mappa, Salvatore Perrone(Sapienza University of Rome), Matteo E. Corti(Istituti di Ricovero e Cura a Carattere Scientifico), Marianna Sassone(Vita-Salute San Raffaele University), Teresa Calimeri(Harvard University), Giuseppe Todeschini(University of Pisa), Maurilio Ponzoni(San Raffaele University of Rome)
Cited by 16
Related Papers
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569